^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | BAL3833 (Src kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
Published date:
10/28/2020
Excerpt:
New drug CCT3833 elicits significant preclinical therapeutic efficacy in KRAS-mutant colorectal, lung and pancreatic tumor xenografts…CCT3833 inhibits KRAS-mutant cancer cell growth...CCT3833 is active against a panel of KRAS-mutant PDAC, CRC and NSCLC cell lines...CT3833 has been evaluated in a phase I clinical trial (NCT02437227) and we report here that it significantly prolongs progression-free survival of a patient with a G12VKRAS spindle cell sarcoma.
DOI:
10.1016/j.annonc.2020.10.483
Trial ID:
